10X Genomics Inc vs Sprott Uranium Miners ETF — how do they compare? 10X Genomics Inc trades at $67.8 (market cap $8.55B), while Sprott Uranium Miners ETF trades at $56.37. The key difference: 10X Genomics Inc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| TXG | URNM | |
|---|---|---|
Market Cap | $8.55B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $67.29 | $83.99 |
52-Week Low | $11.34 | $47.13 |
Enterprise Value | $8.08B | — |
Signals from Pluang's Aura AI — not financial advice
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
URNM, the Sprott Uranium Miners ETF, trades at $57.38, up 0.54% on the day, with a neutral technical signal. Key support lies at $57 and resistance at $58. The ETF offers concentrated exposure to uranium miners, benefiting from long-term supply deficits and rising demand driven by nuclear energy adoption for AI power needs. Recent news highlights strong fundamentals, including government funding and tech company reactor deals.
Outlook remains positive due to structural uranium supply shortages and increasing nuclear energy demand, though volatility risks persist from price swings and geopolitical factors. Analyst sentiment is mixed, with some advocating pure-miner exposure for higher upside, while others caution on valuation divergences from spot uranium prices.
Trailing returns across standard periods
Latest headlines on both assets
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →